Please assess the completion status of the following clinical trial:

Trial Title: Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Anterior circulation aneurysm~* Patients who have undergone surgical intervention~* Absence of rebleeding or new intracranial hemorrhage noted on post-intervention CT scan~* Consent for study participation~Exclusion Criteria:~* Non-aneurysmal subarachnoid hemorrhage~* Multiple ruptured aneurysms~* Patients with congestive heart failure~* Severe aneurysmal subarachnoid hemorrhage (Hunt Hess Grade V)~* Active pathological bleeding~* Allergy to cilostazol~* Positive pregnancy test~* Coagulopathy not caused by anti-coagulant use~* History of hemorrhagic complications (gastrointestinal bleeding, etc)~* Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol~* Patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
- Experimental (Type: EXPERIMENTAL): Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.

Based on this trial design, predict the completion outcome and termination type (if applicable).